Business Context and Reporting Period
Company: pSivida Corp. (Note: Input metadata referenced "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2010
Business Overview: pSivida develops tiny drug delivery products for sustained release of drugs. Key product candidates include Iluvien (licensed to Alimera Sciences for diabetic macular edema), Retisert and Vitrasert (licensed to Bausch & Lomb), and BrachySil (BioSilicon technology for pancreatic cancer). The company relies on collaboration agreements and milestone payments for revenue.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2010 | Nine Months Ended Mar 31, 2010 | Balance Sheet (Mar 31, 2010) |
|---|---|---|---|
| Total Revenues | $0.515 million | $7.331 million | - |
| Net Loss | $(2.705) million | $(4.320) million | - |
| Loss Per Share (Basic/Diluted) | $(0.15) | $(0.24) | - |
| Cash and Cash Equivalents | - | - | $3.971 million |
| Total Assets | - | - | $29.918 million |
| Total Liabilities | - | - | $10.339 million |
| Stockholders' Equity | - | - | $19.579 million |
| Derivative Liabilities | - | - | $2.181 million |
Note: The company reported a net loss for the periods presented. Operating cash flow was negative, with net cash used in operating activities totaling $3.709 million for the nine months ended March 31, 2010.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 84% ($2.6 million) for the three months ended March 31, 2010, compared to the prior year. This was primarily due to the conclusion of the performance period under the Alimera collaboration agreement on December 31, 2009, which had previously generated significant deferred revenue recognition.
- Operating Expenses: Total operating expenses decreased 14% ($0.566 million) for the quarter and 23% ($3.1 million) for the nine months. Reductions were driven by lower UK-based R&D costs (completion of BrachySil Phase II studies) and the absence of prior-year severance costs and provisions for loss on notes receivable.
- Derivative Liability Volatility: The change in fair value of derivative liabilities resulted in income of $0.226 million for the quarter (vs. $0.022 million prior year) but an expense of $1.210 million for the nine months (vs. income of $1.578 million prior year). This volatility is driven by fluctuations in the company's share price relative to warrant exercise prices.
- Cash Position: Cash and cash equivalents declined from $6.899 million at June 30, 2009, to $3.971 million at March 31, 2010.
Guidance, Outlook, and Risks
- Upcoming Revenue Recognition: On April 27, 2010, Alimera repaid a $15.0 million conditional note in full plus accrued interest. Management expects to recognize approximately $15.3 million in collaborative research and development revenue in the quarter ending June 30, 2010.
- Liquidity Outlook: Management believes current cash resources, combined with the recent Alimera payment, are sufficient to fund operations for at least the next 12 months (through March 31, 2011).
- Key Catalysts:
- Iluvien: Alimera plans to file a New Drug Application (NDA) with the FDA in Q2 2010, requesting Priority Review. Approval could lead to commercialization in Q1 2011 and a $25.0 million milestone payment to pSivida.
- Retisert: Royalty income is expected to be recorded in the fourth quarter of the fiscal year ending June 30, 2010, following the exhaustion of an advance payment retention by Bausch & Lomb.
- Risks and Contingencies:
- Derivative Liabilities: Significant fluctuations in the company's stock price will continue to impact the fair value of A$-denominated warrants, creating non-cash volatility in earnings.
- Regulatory Risk: Future revenue is heavily dependent on FDA approval of Iluvien, which is not guaranteed.
- Capital Needs: If product candidates are not approved or commercialized successfully, the company may need to raise additional capital, which could be dilutive.
Investor Verification Checklist
- Alimera NDA Filing: Verify the timing and status of the New Drug Application for Iluvien filed by Alimera Sciences in Q2 2010.
- Revenue Recognition Timing: Confirm the exact timing of the $15.3 million revenue recognition from the Alimera note repayment in the Q2 2010 financial results.
- Derivative Liability Exposure: Monitor the company's share price volatility and its impact on the $2.2 million derivative liability balance.
- Cash Burn Rate: Assess whether the $4.0 million cash balance (plus the $15.2 million Alimera payment) is sufficient to sustain operations if FDA approval is delayed beyond 2011.
- Retisert Royalties: Verify the receipt of royalty payments from Bausch & Lomb in the fourth quarter of fiscal 2010.